Yes, ACE inhibitors and ARBs are feasible and recommended in hemodialysis patients
ACE inhibitors are not contraindicated in patients with end-stage renal disease on hemodialysis and are used frequently in this population 1. The key is selecting the right agent and avoiding specific contraindications.
Critical Selection Criteria
When prescribing ACE inhibitors or ARBs in hemodialysis patients, you must:
Select an ACE inhibitor that is NOT significantly removed by dialysis to maintain stable and sustained therapy 1. Agents with partial hepatic clearance (e.g., fosinopril) are preferred over those solely renally cleared.
Absolutely avoid ACE inhibitors in patients using polyacrylonitrile dialysis membranes due to risk of anaphylactoid dialyzer reactions 1. This is a critical safety concern.
Specific Clinical Indications
For Heart Failure with Reduced Ejection Fraction
ACE inhibitors should be used in hemodialysis patients with CHF and impaired LV function, despite limited data in this population 2. The proven mortality benefit in the general population justifies their use, though dosing schedules must be individualized around dialysis sessions to avoid intradialytic hypotension. One study showed a 30% dropout rate at 6 months due to hypotension with enalapril 2.
ARBs appear superior to ACEIs for cardiovascular outcomes in hemodialysis patients based on the most recent high-quality evidence. A 2026 real-world cohort of 55,894 matched patients showed ARBs were associated with lower risk of major adverse cardiovascular events (HR 0.85), stroke (HR 0.90), and all-cause mortality (HR 0.75) compared to ACEIs 3. This finding was consistent across subgroups including diabetes, heart failure, and coronary artery disease.
For Hypertension
Both ACE inhibitors and ARBs are appropriate first-line agents for hypertension management in hemodialysis patients 2. However, ARBs may be preferred given their superior cardiovascular outcomes 3.
Practical Dosing Considerations
- Time doses to avoid intradialytic hypotension - this is the most common complication requiring dose adjustment 2
- Monitor for hyperkalemia, though rates are comparable between ARBs and ACEIs 3
- Start at lower doses and titrate carefully
- Hemodialysis removes some ACE inhibitors (enalapril, ramipril) but not others (benazepril, fosinopril) or ARBs 2
Important Caveats
The combination of ACE inhibitor + ARB should be avoided in hemodialysis patients. A 2017 Japanese cohort study showed combination therapy was associated with significantly increased mortality (adjusted IRR 2.56) compared to non-users, despite ARB monotherapy showing benefit 4.
Evidence for mortality benefit remains mixed. While observational studies suggest benefit (particularly with ARBs), a 2023 meta-analysis of 5 RCTs involving 1,582 dialysis patients found no significant reduction in cardiovascular events (RR 0.79), cardiovascular mortality (RR 0.82), or all-cause mortality (RR 0.86) with ACEIs/ARBs versus placebo 5. However, the most recent 2026 observational data strongly favors ARBs over ACEIs 3, and a 2026 meta-analysis showed both ARNIs and ACEi/ARBs were associated with lower all-cause mortality in dialysis patients with HFrEF 6.
Bottom Line Algorithm
- First choice: ARB (not significantly dialyzed) for hypertension or heart failure
- Alternative: ACE inhibitor with partial hepatic clearance (e.g., fosinopril)
- Verify: Patient is NOT using polyacrylonitrile dialysis membranes
- Dose: Time administration to avoid intradialytic hypotension
- Monitor: Blood pressure response and potassium levels
- Avoid: Combination ACE inhibitor + ARB therapy